Cyclophosphamide

Overview

Cyclophosphamide (Cytoxan®, Neosar®) is an alkylating antineoplastic drug widely used in veterinary oncology for the treatment of various cancers in dogs and cats. It is commonly included in combination chemotherapy protocols for lymphoid and myeloproliferative diseases and may also be used in some sarcomas and carcinomas.

In dogs, cyclophosphamide may also be used as part of metronomic chemotherapy protocols, where low doses are administered continuously to inhibit tumor angiogenesis and tumor growth. This approach may produce fewer adverse effects than traditional high-dose chemotherapy in some patients.

Mechanism of Action (MOA): Cyclophosphamide is a prodrug that is metabolized in the liver to active cytotoxic metabolites, primarily 4-hydroxycyclophosphamide. These metabolites form alkylating compounds that interfere with DNA replication and RNA transcription, ultimately disrupting nucleic acid function and preventing tumor cell proliferation. The drug also has immunosuppressive effects due to reduced white blood cell and antibody production.

Indications

Cyclophosphamide is commonly used in dogs and cats as part of chemotherapy protocols for the treatment of various malignant diseases. It is most frequently administered in combination with other antineoplastic agents to improve treatment response and remission rates.

• Lymphoid neoplasia: One of the primary indications for cyclophosphamide in dogs and cats, particularly as part of multi-drug chemotherapy protocols for lymphoma and other lymphoproliferative disorders.
• Myeloproliferative diseases: May be used in the management of certain bone marrow–related malignancies affecting blood cell production.
• Metronomic chemotherapy protocols (dogs): Low-dose continuous administration may be used to help inhibit tumor angiogenesis and slow tumor progression, sometimes with fewer adverse effects than traditional high-dose chemotherapy.
• Selected sarcomas and carcinomas: Cyclophosphamide may be included in chemotherapy protocols for certain soft tissue sarcomas or carcinomas when clinically indicated.

Dosage (Reference)

Dog

In dogs, cyclophosphamide may be given orally or intravenously depending on the chemotherapy protocol being used. The dose and schedule vary depending on the type of cancer and whether the drug is used in standard chemotherapy protocols or in low-dose (metronomic) therapy.

Cat

In cats, cyclophosphamide is primarily used in chemotherapy protocols for lymphoid neoplasia. The dosing regimen is similar to that used in dogs, although higher doses may be used in certain high-dose chemotherapy protocols.

Warnings & Precautions

Cyclophosphamide is a potent chemotherapy drug and should only be used in patients that can be closely monitored during treatment. Careful patient selection and regular laboratory monitoring are essential because the drug can cause serious toxic effects.

• Previous hypersensitivity: Cyclophosphamide should not be used in animals with a history of anaphylactic reactions to this drug.
• Sterile hemorrhagic cystitis: Avoid use in animals with a history of sterile hemorrhagic cystitis. If this condition develops during treatment, the drug should be discontinued and future use considered contraindicated.
• Urinary tract conditions: Use cautiously in patients with urinary tract infections or urinary obstruction, as the drug may worsen urinary complications.
• Renal or hepatic impairment: Animals with kidney or liver dysfunction may require dose adjustment and close monitoring during therapy.
• Myelosuppression risk: Use cautiously in patients with leukopenia or thrombocytopenia. If significant bone marrow suppression occurs, additional doses should be delayed until recovery.
• Concurrent radiation therapy: Animals receiving radiotherapy may have an increased risk of toxicity and should be monitored carefully.
• Risk of immunosuppression: Because cyclophosphamide suppresses immune function, use cautiously in animals with active infections or conditions where immunosuppression may be dangerous.
• Hydration and urination: Adequate hydration and frequent urination are recommended to reduce the risk of bladder toxicity caused by drug metabolites.
• Hazardous drug handling: Cyclophosphamide is classified as a hazardous drug by the National Institute for Occupational Safety and Health (NIOSH). Appropriate protective equipment should be used when handling the medication.
• Pregnancy risk: The drug is potentially teratogenic and fetotoxic. Pregnancy status should be verified in sexually intact females before administration.

Drug Interactions

Cyclophosphamide may interact with several medications, mainly by increasing the risk of bone marrow suppression, organ toxicity, or altered drug metabolism. When used together with the following drugs, careful monitoring and dose adjustment may be required.

• Allopurinol: Concurrent use may increase the risk of bone marrow suppression.
• Amiodarone: May increase the risk of pulmonary toxicity when used with cyclophosphamide.
• Amphotericin B: Concurrent administration may increase the risk of kidney toxicity.
• Azathioprine: May increase the risk of liver toxicity when used together.
• Cardiotoxic drugs (e.g., doxorubicin, cytarabine): Concurrent use may increase the risk of cardiac toxicity.
• Cyclosporine: Cyclophosphamide may reduce cyclosporine blood concentrations, while also increasing the overall immunosuppressive effect.
• Dipyrone: Concurrent use may increase the risk of agranulocytosis and pancytopenia.
• Other immunosuppressive drugs (e.g., leflunomide, tacrolimus): May enhance immunosuppressive effects when used together.
• Myelosuppressive drugs (e.g., carboplatin, vincristine): May increase the risk of neutropenia and other blood cell abnormalities.
• Thiazide diuretics (e.g., hydrochlorothiazide): May increase cyclophosphamide exposure and worsen bone marrow suppression.
• Ondansetron: May decrease systemic exposure to cyclophosphamide.
• Phenobarbital (and other barbiturates): Chronic use may increase metabolism of cyclophosphamide and increase the risk of toxicity.
• Live vaccines: Cyclophosphamide may reduce vaccine effectiveness due to its immunosuppressive effects.
• Warfarin: Concurrent use may increase the risk of bleeding.

Side Effects & Overdose

Side Effects

The most common adverse effects of cyclophosphamide in dogs and cats are related to bone marrow suppression, gastrointestinal irritation, and urinary tract toxicity. The severity of these effects can vary depending on the dose, treatment duration, and concurrent chemotherapy drugs.

• Myelosuppression: The most significant adverse effect, including leukopenia, neutropenia, anemia, and occasionally thrombocytopenia. The lowest white blood cell count (nadir) typically occurs about 5–14 days after dosing and recovery may take several weeks.
• Gastrointestinal effects: Loss of appetite, nausea, vomiting, and diarrhea may occur. Cats may show anorexia more frequently.
• Sterile hemorrhagic cystitis: Inflammation and bleeding of the bladder caused by the metabolite acrolein. Clinical signs may include hematuria, dysuria, or frequent urination. This effect is more common in dogs receiving long-term therapy.
• Hair coat changes: Many dogs receiving chemotherapy develop mild coat changes such as dull hair or shagginess. Breeds with continuously growing hair coats (e.g., poodles, terriers, Afghan hounds, old English sheepdogs) may develop more noticeable hair loss.
• Other possible toxicities: Less commonly, hepatic, renal, pulmonary, or cardiac toxicity may occur.

Overdose

Information about acute overdose in veterinary patients is limited, but excessive exposure may intensify the drug’s toxic effects, particularly bone marrow suppression and gastrointestinal complications.

• Clinical signs: Possible signs include vomiting, anorexia, hematuria, excessive thirst, electrolyte abnormalities, neurologic signs (such as tremors or seizures), and severe neutropenia.
• Supportive treatment: Management typically includes hospitalization, fluid therapy, monitoring of blood cell counts, and treatment of complications such as infection or bleeding.
• Bone marrow support: Recombinant canine granulocyte colony-stimulating factor (rcG-CSF) may be used in some cases to help stimulate white blood cell recovery.
• Decontamination: If an oral overdose is suspected and detected early, gastrointestinal decontamination and intensive supportive care may be indicated.
• Dialysis: Cyclophosphamide is considered moderately dialyzable, so dialysis may be beneficial in certain severe overdose situations.

Key Notes

Practical clinical points that may help optimize the safe and effective use of cyclophosphamide in dogs and cats:

• Prodrug activation: Cyclophosphamide itself is inactive and must be metabolized in the liver to form its active cytotoxic metabolites that target rapidly dividing tumor cells.
• Route flexibility: In dogs, oral and intravenous administration generally produce similar exposure to the active metabolite, so either route may be used depending on the chemotherapy protocol.
• Morning administration: Giving the drug earlier in the day may help encourage urination throughout the day, which can reduce the contact time of drug metabolites with the bladder.
• Monitoring response: Treatment success is usually assessed by monitoring tumor response or remission status in addition to routine laboratory testing.
• Chemotherapy protocols: Cyclophosphamide is most commonly used as part of combination chemotherapy protocols rather than as a single-agent treatment.
• Prescription safety: The drug name may be confused with other medications (e.g., cyclosporine). Writing part of the name in uppercase letters when prescribing can help reduce medication errors.